Q-omics provides the consensus-scored TPI1P3 profile across patient tissues and cancer cell-line models. TPI1P3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TPI1P3 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TPI1P3 RNA expression shows 16,720 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, KIRC, and HNSC as cancer lineages where TPI1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPI1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPI1P3 survival associations across molecular data types. TPI1P3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPI1P3 RNA expression–survival associations across cancer types. High TPI1P3 expression shows unfavorable associations in UVM, ACC and BRCA, but favorable associations in LUSC, CESC and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TPI1P3 RNA expression.
This table summarizes TPI1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TPI1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPI1P3 shows higher tumor expression in KIRC, HNSC, LUAD, LUSC, COAD and BRCA. The KIRC box plot shows higher TPI1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.221, t-test p < 0.001).
This table shows molecular features associated with TPI1P3 in patient tissues and cancer cell lines. In patient samples, TPI1P3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TPI1P3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC.
